Why testing and diagnosis for Alzheimer's disease are mission critical
Abstract The author, a physician who has younger‐onset Alzheimer's disease (AD), recounts his recent lunch with a former coworker who has had a stroke. The author makes the point that because we now have an effective treatment for AD, and phosphorylated tau217 is a sensitive and specific screen...
Saved in:
| Main Author: | Brent W. Beasley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70126 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
by: Triana Amen, et al.
Published: (2016-03-01) -
The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment
by: Julius Mulumba, et al.
Published: (2025-02-01) -
Catalpol alleviates amyloid- generation and neuronal oxidative stress injury via activating the Keap1-Nrf2/ARE signaling pathway in the immortalized lymphocytes from patients with late-onset Alzheimer’s disease and SKNMC cells co-culture model
by: Caixia Xiang, et al.
Published: (2024-12-01) -
Diagnosis and Treatment of Alzheimer’s Disease: Current Update
by: Younghee Yim, et al.
Published: (2025-01-01) -
Beneficial Influence of Agomelatine Treatment on Behavioral Impairments in AΒ-Induced Rat Model of Alzheimer’s Disease
by: Kalina Ilieva, et al.
Published: (2020-12-01)